ABOUT
Overview
Executive Management
Board of Directors
PRODUCTS
Pliaglis
PIPELINE
INVESTORS
Overview
Annual General Meeting
Corporate Governance
Shareholder Information
Stock Quote
Press Releases
Financial Reporting
Presentations
Request Information
TECHNOLOGY
Overview
MMPE
DuraPeel
CONTACT
Navigate to...
ABOUT
– Overview
– Executive Management
– Board of Directors
PRODUCTS
– Pliaglis
PIPELINE
INVESTORS
– Overview
– Corporate Governance
– Shareholder Information
– Stock Quote
– Press Releases
– Financial Reporting
– Presentations
– Request Information
TECHNOLOGY
– Overview
– MMPE
– DuraPeel
CONTACT
Press Releases
Home
»
Investors
»
Press Releases
Recent News
Year
All Years
2021
2020
2019
2018
2017
2016
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Nov 26, 2020
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Nov 12, 2020
Crescita Reports Third Quarter 2020 Results
Nov 5, 2020
Crescita Announces Licensing Agreement for Pliaglis® in China
Aug 12, 2020
Crescita Reports Second Quarter 2020 Results
Jul 28, 2020
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement
May 27, 2020
Crescita Reports First Quarter 2020 Results
May 14, 2020
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders
Apr 28, 2020
Crescita Therapeutics Announces Extension of First Quarter 2020 Filings Due to COVID-19
Mar 24, 2020
Crescita Therapeutics Announces Measures in Response to COVID-19 Virus
Mar 18, 2020
Crescita Reports Q4 and Fiscal 2019 Results
Feb 11, 2020
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis
Jan 24, 2020
Crescita Awarded Cannabis Research License from Health Canada
Jan 22, 2020
Crescita Secures Line of Credit with the Royal Bank of Canada Following Repayment in Full of Knight Therapeutics Loan
Jan 20, 2020
Crescita Signs Exclusive Distribution Agreement with FILLMED
Nov 7, 2019
Crescita Reports 2019 Third Quarter Results
Nov 5, 2019
U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®
Oct 28, 2019
Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals
Sep 5, 2019
Crescita Therapeutics Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City
Aug 8, 2019
Crescita Reports Profitable 2019 Second Quarter Results
Jul 16, 2019
United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®
Jul 11, 2019
Crescita Therapeutics to Host Investor Webcast on July 24, 2019
Jul 4, 2019
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy
Jun 26, 2019
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Jun 17, 2019
Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid
May 30, 2019
Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California
May 29, 2019
Crescita Therapeutics Engages Bristol Capital to Provide Investor Relations and Communications Services
May 15, 2019
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
May 15, 2019
Crescita Therapeutics Reports 2019 First Quarter Results
May 7, 2019
Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit
Apr 25, 2019
Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement with Cantabria Labs for €2.5M Upfront After Reacquiring Rest-of-World Rights
Apr 17, 2019
Crescita Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto
Mar 21, 2019
Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones
Feb 4, 2019
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio
Dec 17, 2018
U.S. FDA Approves Removal of "Not for Home Use" Label Restriction for Pliaglis®
Nov 9, 2018
Crescita Therapeutics™ Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M
Nov 8, 2018
Crescita Reinvigorates Skincare Line Leveraging its MMPE™ Technology and Becomes One of the First Companies Worldwide to Release Anti-Ageing Formulation Using ECOBIOTYS®
Oct 15, 2018
Crescita's Patented Delivery Technologies Demonstrate Enhanced Skin Permeation of Cannabidiol
Aug 10, 2018
Crescita Therapeutics™ Reports 2018 Second Quarter Results
Jun 13, 2018
Crescita Therapeutics™ Announces Director Election Results of its Annual General Meeting
May 9, 2018
Crescita Therapeutics™ Reports 2018 First Quarter Results
Apr 26, 2018
Crescita Therapeutics™ To Present at the 2018 Bloom Burton &Co. Healthcare Investor Conference in Toronto
Apr 5, 2018
Crescita Therapeutics Inc. Adds Recognized Skincare Expert to its Leadership Team
Apr 3, 2018
Crescita Therapeutics™ Announces the Appointment of Serge Verreault as President & CEO
Mar 29, 2018
Crescita Announces Launch of Pliaglis in U.S.
Mar 28, 2018
Crescita Therapeutics™ Reports 2017 Fourth Quarter and Year End Results
Mar 12, 2018
Crescita Therapeutics Inc. Announces Completion of Oversubscribed Rights Offering
Jan 31, 2018
Crescita Therapeutics Inc. Announces Rights Offering to Raise Up To $3.7 Million
Nov 10, 2017
Crescita Therapeutics™ Announces 2017 Third Quarter Results and Appoints New CFO
Sep 18, 2017
Crescita Therapeutics™ Reports Positive Topline Results of Phase 2 Clinical Trial for the Treatment of Plaque Psoriasis
Aug 29, 2017
Crescita Therapeutics™ Announces Completion of $1.0 million Convertible Debenture Financing with Bloom Burton Funds
Aug 14, 2017
Crescita Therapeutics™ Announces Profitable 2017 Second Quarter Results
Aug 14, 2017
Crescita Therapeutics™ Announces Amended Loan Agreement with Knight Therapeutics
Aug 8, 2017
Crescita Therapeutics™ Announces Acquisition of Alyria® Skincare Products
Jun 20, 2017
Crescita Therapeutics™ Announces Director Election Results of its Annual General Meeting
May 15, 2017
Crescita Therapeutics™ Announces 2017 First Quarter Results
Apr 25, 2017
Crescita Therapeutics™ Announces Agreement with Taro Pharmaceuticals for Pliaglis®
Apr 12, 2017
Crescita Therapeutics™ Announces the Appointment of a New President
Mar 30, 2017
Crescita Therapeutics™ Announces 2016 Fourth Quarter and Year-End Results
Mar 21, 2017
Crescita Therapeutics™ Announces Signing of a Licensing Agreement Utilizing its MMPE™ Technology
Feb 10, 2017
Crescita Therapeutics™ Announces Management and Board Changes
Jan 26, 2017
Crescita Therapeutics™ Announces Launch of ISDIN® Product Line at Brunet Pharmacy
Nov 14, 2016
Crescita Therapeutics(TM) Announces 2016 Third Quarter Results
Nov 3, 2016
Crescita Appoints Dan Chicoine as Interim CEO
Sep 29, 2016
Crescita Therapeutics™ Announces Changes to the Board of Directors
Sep 9, 2016
Crescita Therapeutics™ Announces Approval of Pliaglis in Mexico
Sep 1, 2016
Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
Jul 27, 2016
Crescita Therapeutics™ Announces 2016 Second Quarter Results
Jul 12, 2016
Crescita Therapeutics™ Provides an Update on its Immunology Group Wind-Down
May 10, 2016
Crescita Therapeutics™ Announces 2016 First Quarter Results
Mar 7, 2016
Crescita Therapeutics™ Inc. Provides Corporate Update
Mar 1, 2016
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies
Show
5
10
25
50
100
per page
Back To Top
